hotspot -WSS

hotspot

author：focus 2025-09-06 04:37:00 - browse：6

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Four alarming medical procedures we’re glad history forgot

WSS

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Bird flu in dairy cattle: New measures to control spread to humans

People with mental disorders often marry others with same

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Mass General Brigham physicians react to latest merger step

Maker of FluMist seeks to allow at

knowledge

hotspot

focus

Peter Hotez and the public health issue of online harassment

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Malaria cases in Florida and Texas: Here’s what you need to know

Medtronic CEO on promising devices for diabetes, hypertension

At least 13 dead in Texas as scorching temps continue

Oral obesity drug from Viking Therapeutics hits key early target

Trump demands the U.S. pay no more for drugs than other countries … again

Alzheimer's risk factor APOE4 may be a distinct form of the disease

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why Sanofi got shellacked over its spinoff

leisure time

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Meta's Zuckerberg and Chan on track to put $50 billion into science

Bird flu reported in person exposed to presumably infected cattle

Maker of FluMist seeks to allow at

Trial using CRISPR to edit HIV out of cells disappoints

Trial using CRISPR to edit HIV out of cells disappoints

focus

explore

Wikipedia

knowledge